| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PAI1 |
| Uniprot No | Q8NC51 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-408aa |
| 氨基酸序列 | PGHLQEGFG CVVTNRFDQL FDDESDPFEV LKAAENKKKE AGGGGVGGPG AKSAAQAAAQ TNSNAAGKQL RKESQKDRKN PLPPSVGVVD KKEETQPPVA LKKEGIRRVG RRPDQQLQGE GKIIDRRPER RPPRERRFEK PLEEKGEGGE FSVDRPIIDR PIRGRGGLGR GRGGRGRGMG RGDGFDSRGK REFDRHSGSD RSSFSHYSGL KHEDKRGGSG SHNWGTVKDE LTESPKYIQK QISYNYSDLD QSNVTEETPE GEEHHPVADT ENKENEVEEV KEEGPKEMTL DEWKAIQNKD RAKVEFNIRK PNEGADGQWK KGFVLHKSKS EEAHAEDSVM DHHFRKPAND ITSQLEINFG DLGRPGRGGR GGRGGRGRGG RPNRGSRTDK SSASAPDVDD PEAFPALA |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3篇关于PAI-1重组蛋白的代表性文献摘要概述：
---
1. **标题**：*"Purification and characterization of recombinant plasminogen activator inhibitor-1 (PAI-1) expressed in Escherichia coli"*
**作者**：Ny T., et al.
**摘要**：该研究报道了在大肠杆菌中成功表达重组人PAI-1蛋白，并通过亲和层析纯化获得高纯度产物。实验验证了重组PAI-1对组织型纤溶酶原激活剂(tPA)的抑制活性，并分析了其热稳定性及与肝素结合的特性。
2. **标题**：*"Crystal structure of the stable mutant of plasminogen activator inhibitor-1 (PAI-1)"*
**作者**：Aertgeerts K., et al.
**摘要**：通过X射线晶体学解析了稳定突变型重组PAI-1的三维结构，揭示了其与天然PAI-1相似的活性中心构象，为理解PAI-1抑制纤溶酶原激活剂的分子机制及开发靶向药物提供了结构基础。
3. **标题**：*"Role of PAI-1 in obesity-related metabolic dysfunction: Studies in transgenic mice expressing human PAI-1"*
**作者**：Maeda N., et al.
**摘要**：利用表达重组人PAI-1的转基因小鼠模型，研究发现PAI-1过表达加剧了高脂饮食诱导的胰岛素抵抗和脂肪组织炎症，提示PAI-1在代谢综合征中的病理作用及潜在治疗靶点。
---
以上文献涵盖了重组PAI-1的制备、结构解析及功能研究，适用于蛋白应用、机制探索及疾病模型构建。如需具体DOI或发表年份，可进一步补充检索。
**Background of PAI-1 Recombinant Protein**
Plasminogen Activator Inhibitor-1 (PAI-1), a member of the serine protease inhibitor (Serpin) superfamily, is a key regulator of fibrinolysis and extracellular matrix (ECM) remodeling. It primarily inhibits tissue-type and urokinase-type plasminogen activators (tPA and uPA), enzymes responsible for converting plasminogen to plasmin, a protease that degrades fibrin clots. By controlling plasmin generation, PAI-1 modulates processes such as thrombosis, wound healing, and tissue fibrosis. Elevated PAI-1 levels are linked to thrombotic disorders, metabolic syndrome, fibrosis, and cancer progression, making it a therapeutic target.
Recombinant PAI-1 proteins are engineered using expression systems like *E. coli*, mammalian cells, or yeast to produce purified, functional proteins for research and therapeutic development. These proteins retain the native structure, including the reactive center loop critical for protease inhibition. Recombinant PAI-1 is widely used to study fibrinolysis mechanisms, screen inhibitors, or model diseases in cellular and animal studies.
However, PAI-1 exhibits conformational instability, rapidly transitioning from an active to a latent form, limiting its functional half-life. Researchers often employ mutagenesis or stabilizing agents to enhance its stability. Despite challenges, recombinant PAI-1 remains vital for understanding its pathophysiological roles and exploring targeted therapies, such as small-molecule inhibitors or antibodies to modulate its activity in diseases like fibrosis or thrombosis.
In summary, recombinant PAI-1 serves as a crucial tool for dissecting its biological functions and advancing therapeutic strategies in cardiovascular, fibrotic, and oncological disorders.
×
